Jeffrey R. Dahlen

815 total citations
20 papers, 663 citations indexed

About

Jeffrey R. Dahlen is a scholar working on Cancer Research, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, Jeffrey R. Dahlen has authored 20 papers receiving a total of 663 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cancer Research, 7 papers in Cardiology and Cardiovascular Medicine and 6 papers in Molecular Biology. Recurrent topics in Jeffrey R. Dahlen's work include Protease and Inhibitor Mechanisms (8 papers), Antiplatelet Therapy and Cardiovascular Diseases (6 papers) and Atrial Fibrillation Management and Outcomes (5 papers). Jeffrey R. Dahlen is often cited by papers focused on Protease and Inhibitor Mechanisms (8 papers), Antiplatelet Therapy and Cardiovascular Diseases (6 papers) and Atrial Fibrillation Management and Outcomes (5 papers). Jeffrey R. Dahlen collaborates with scholars based in United States, Japan and Spain. Jeffrey R. Dahlen's co-authors include Donald C. Foster, Walter Kisiel, Mark A. Reynolds, Paul McPherson, Daniel T. Laskowitz, G E Valkirs, Kenneth F. Buechler, Cindy A. Sprecher, HOWARD J. KIRCHICK and Gary Thomas and has published in prestigious journals such as Journal of Biological Chemistry, Biochemistry and Biochemical Journal.

In The Last Decade

Jeffrey R. Dahlen

20 papers receiving 641 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey R. Dahlen United States 13 301 167 137 124 107 20 663
Sofie Starckx Belgium 14 222 0.7× 228 1.4× 78 0.6× 165 1.3× 189 1.8× 19 789
Chirosree Bandyopadhyay United States 10 401 1.3× 141 0.8× 134 1.0× 24 0.2× 110 1.0× 10 788
Andrew Bantly United States 13 294 1.0× 47 0.3× 82 0.6× 87 0.7× 103 1.0× 19 538
Roberto Caporale Italy 14 243 0.8× 28 0.2× 76 0.6× 150 1.2× 123 1.1× 23 633
Kohei Hosokawa Japan 17 177 0.6× 104 0.6× 139 1.0× 341 2.8× 311 2.9× 80 903
Heidi Kenis Netherlands 13 512 1.7× 50 0.3× 42 0.3× 160 1.3× 263 2.5× 18 875
Valentina Bevelacqua Italy 13 258 0.9× 94 0.6× 91 0.7× 53 0.4× 269 2.5× 22 743
B J Marafino United States 12 195 0.6× 85 0.5× 80 0.6× 71 0.6× 168 1.6× 15 658
Lu Cui China 16 345 1.1× 45 0.3× 94 0.7× 99 0.8× 165 1.5× 31 835
Philip H. Johnson United Kingdom 16 485 1.6× 49 0.3× 76 0.6× 178 1.4× 107 1.0× 33 948

Countries citing papers authored by Jeffrey R. Dahlen

Since Specialization
Citations

This map shows the geographic impact of Jeffrey R. Dahlen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey R. Dahlen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey R. Dahlen more than expected).

Fields of papers citing papers by Jeffrey R. Dahlen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey R. Dahlen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey R. Dahlen. The network helps show where Jeffrey R. Dahlen may publish in the future.

Co-authorship network of co-authors of Jeffrey R. Dahlen

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey R. Dahlen. A scholar is included among the top collaborators of Jeffrey R. Dahlen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey R. Dahlen. Jeffrey R. Dahlen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peabody, John, David Paculdo, Peter A. McCullough, et al.. (2022). Clinical Utility of a Biomarker to Detect Contrast-Induced Acute Kidney Injury during Percutaneous Cardiovascular Procedures. Cardiorenal Medicine. 12(1). 11–19. 6 indexed citations
2.
Gurbel, Paul A., Udaya S. Tantry, Kevin P. Bliden, et al.. (2021). Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists. Journal of Thrombosis and Thrombolysis. 52(1). 272–280. 1 indexed citations
3.
Tantry, Udaya S., et al.. (2021). First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19. Open Forum Infectious Diseases. 8(7). ofab274–ofab274. 19 indexed citations
4.
McCullough, Peter A., David Paculdo, Maria Czarina Acelajado, et al.. (2021). Measuring the Variation in the Prevention and Treatment of CI-AKI Among Interventional Cardiologists. Current Problems in Cardiology. 46(9). 100851–100851. 4 indexed citations
5.
Wallén, Håkan, Dániel Aradi, Thea C. Godschalk, et al.. (2021). The Total Thrombus Formation (T-TAS) platelet (PL) assay, a novel test that evaluates whole blood platelet thrombus formation under physiological conditions. Platelets. 33(2). 273–277. 10 indexed citations
6.
Peabody, John, David Paculdo, Maria Czarina Acelajado, Trever Burgon, & Jeffrey R. Dahlen. (2020). Finding the clinical utility of 1,5-anhydroglucitol among primary care practitioners. Journal of Clinical & Translational Endocrinology. 20. 100224–100224. 3 indexed citations
7.
Hosokawa, Kazuya, et al.. (2020). New methodological approaches for assessing thrombus formation in cardiovascular disease. Kardiologia Polska. 78(7-8). 667–673. 3 indexed citations
8.
Kaikita, Koichi, Kazuya Hosokawa, Jeffrey R. Dahlen, & Kenichi Tsujita. (2019). Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation in Cardiovascular Disease. Thrombosis and Haemostasis. 119(10). 1554–1562. 47 indexed citations
9.
Peabody, John, et al.. (2019). Variation in Diabetes Management: A National Assessment of Primary Care Providers. Journal of Diabetes Science and Technology. 14(1). 70–76. 4 indexed citations
10.
Price, Matthew J., Helen Parise, Paul A. Gurbel, & Jeffrey R. Dahlen. (2012). Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures. Thrombosis and Haemostasis. 109(5). 808–816. 31 indexed citations
11.
Jakubowski, Joseph A., et al.. (2011). Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y12antagonism. Platelets. 22(8). 619–625. 13 indexed citations
12.
Reynolds, Mark A., HOWARD J. KIRCHICK, Jeffrey R. Dahlen, et al.. (2003). Early Biomarkers of Stroke. Clinical Chemistry. 49(10). 1733–1739. 191 indexed citations
13.
Dahlen, Jeffrey R., Donald C. Foster, & Walter Kisiel. (1999). Inhibition of neutrophil elastase by recombinant human proteinase inhibitor 9. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1451(2-3). 233–241. 18 indexed citations
14.
Annand, R. R., Jeffrey R. Dahlen, Cindy A. Sprecher, et al.. (1999). Caspase-1 (interleukin-1β-converting enzyme) is inhibited by the human serpin analogue proteinase inhibitor 9. Biochemical Journal. 342(3). 655–665. 88 indexed citations
15.
Dahlen, Jeffrey R., et al.. (1999). Caspase-1 (interleukin-1β-converting enzyme) is inhibited by the human serpin analogue proteinase inhibitor 9. Biochemical Journal. 342(3). 655–655. 14 indexed citations
16.
Dahlen, Jeffrey R., François Jean, Gary Thomas, Donald C. Foster, & Walter Kisiel. (1998). Inhibition of Soluble Recombinant Furin by Human Proteinase Inhibitor 8. Journal of Biological Chemistry. 273(4). 1851–1854. 79 indexed citations
17.
Dahlen, Jeffrey R., Donald C. Foster, & Walter Kisiel. (1998). The Inhibitory Specificity of Human Proteinase Inhibitor 8 Is Expanded through the Use of Multiple Reactive Site Residues. Biochemical and Biophysical Research Communications. 244(1). 172–177. 16 indexed citations
18.
Dahlen, Jeffrey R., Donald C. Foster, & Walter Kisiel. (1997). Human Proteinase Inhibitor 9 (PI9) Is a Potent Inhibitor of Subtilisin A. Biochemical and Biophysical Research Communications. 238(2). 329–333. 20 indexed citations
19.
Dahlen, Jeffrey R., Donald C. Foster, & Walter Kisiel. (1997). Expression, Purification, and Inhibitory Properties of Human Proteinase Inhibitor 8. Biochemistry. 36(48). 14874–14882. 25 indexed citations
20.
Sprecher, Cindy A., Kurt Morgenstern, Shannon Mathewes, et al.. (1995). Molecular Cloning, Expression, and Partial Characterization of Two Novel Members of the Ovalbumin Family of Serine Proteinase Inhibitors. Journal of Biological Chemistry. 270(50). 29854–29861. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sofie Starckx Breakdown of academic impact, for papers by Chirosree Bandyopadhyay Breakdown of academic impact, for papers by Andrew Bantly Breakdown of academic impact, for papers by Roberto Caporale Breakdown of academic impact, for papers by Kohei Hosokawa Breakdown of academic impact, for papers by Heidi Kenis Breakdown of academic impact, for papers by Valentina Bevelacqua Breakdown of academic impact, for papers by B J Marafino Breakdown of academic impact, for papers by Lu Cui Breakdown of academic impact, for papers by Philip H. Johnson
Rankless by CCL
2026